{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:08:10Z","timestamp":1790842090033,"version":"4.1.0"},"reference-count":39,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"xx","award":["Cathedra DeCo Micof-UCH"],"award-info":[{"award-number":["Cathedra DeCo Micof-UCH"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00594"],"award-info":[{"award-number":["PI22\/00594"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It has been hypothesized that insulin resistance is pivotal in mediating amyloid and tau dysregulations in Alzheimer's disease (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the impact of different antidiabetic agents, their daily dosage intake, and treatment duration on cerebrospinal fluid (CSF) AD biomarkers among patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This cross-sectional study selected patients between 50 and 80 years with diabetes and CSF AD biomarkers screened between 2017 and 2023 in the VALCODIS Cohort. CSF biomarkers were total tau (t-tau), phosphorylated tau 181 (p-tau), and amyloid-\u03b2 42 (A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ). Analytical variables were obtained. Antidiabetic prescriptions were recorded in defined daily doses (DDD), according to the ATC\/DDD 2021 system, and years of drug exposure duration before lumbar puncture. Logistic regressions were performed to establish the correlations between drug usage and AD biomarker alteration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among patients with diabetes, Insulin consumption was associated with lower odds of abnormal A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      levels (OR 0.36 [95% CI 0.15, 0.76]) and tau pathology (OR 0.49 [95% CI 0.24\u20130.98]). Metformin was related to lower odds of pathological p-tau when diabetes was uncontrolled, acting on t-tau and t-tau\/A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ratio when it was concomitant with insulin, and patients had controlled diabetes. Lower odds of pathological levels of tau were observed when additional oral antidiabetic drugs were added among metformin users. iSGLT2 was associated with tau pathology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The impact of antidiabetics on AD-related pathological biomarkers may depend on diabetes management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877241304995","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T02:18:58Z","timestamp":1734401938000},"page":"758-774","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Associations between antidiabetic medications and cerebrospinal fluid biomarkers of Alzheimer's disease"],"prefix":"10.1177","volume":"103","author":[{"given":"Gemma","family":"Garc\u00eda-Lluch","sequence":"first","affiliation":[{"name":"Research Group in Alzheimer Disease, Health Research Institute La Fe, Valencia, Spain"},{"name":"Cathedra DeCo MICOF-CEU UCH, University Cardenal Herrera-CEU, Valencia, Spain"},{"name":"Department of Pharmacy, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Marseglia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain"},{"name":"Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrecia Moreno","family":"Royo","sequence":"additional","affiliation":[{"name":"Cathedra DeCo MICOF-CEU UCH, University Cardenal Herrera-CEU, Valencia, Spain"},{"name":"Department of Pharmacy, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pardo","family":"Albiach","sequence":"additional","affiliation":[{"name":"Embedded Systems and Artificial Intelligence Group, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Garcia-Zamora","sequence":"additional","affiliation":[{"name":"Research Group in Alzheimer Disease, Health Research Institute La Fe, Valencia, Spain"},{"name":"Cathedra DeCo MICOF-CEU UCH, University Cardenal Herrera-CEU, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-1831","authenticated-orcid":false,"given":"Miquel","family":"Baquero","sequence":"additional","affiliation":[{"name":"Research Group in Alzheimer Disease, Health Research Institute La Fe, Valencia, Spain"},{"name":"Cathedra DeCo MICOF-CEU UCH, University Cardenal Herrera-CEU, Valencia, Spain"},{"name":"Neurology Unit, University and Polytechnic Hospital La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3565-1148","authenticated-orcid":false,"given":"Carmen","family":"Pe\u00f1a-Bautista","sequence":"additional","affiliation":[{"name":"Research Group in Alzheimer Disease, Health Research Institute La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Research Group in Alzheimer Disease, Health Research Institute La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Westman","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0711-5877","authenticated-orcid":false,"given":"Consuelo","family":"Ch\u00e1fer-Peric\u00e1s","sequence":"additional","affiliation":[{"name":"Research Group in Alzheimer Disease, Health Research Institute La Fe, Valencia, Spain"},{"name":"Cathedra DeCo MICOF-CEU UCH, University Cardenal Herrera-CEU, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23761"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411450"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i6.745"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102042"},{"key":"e_1_3_5_7_2","first-page":"1688","article-title":"State of the science on brain insulin resistance and cognitive decline due to Alzheimer\u2019s disease","volume":"15","author":"Rhea EM","year":"2024","unstructured":"Rhea EM, Leclerc M, Yassine HN, et al. State of the science on brain insulin resistance and cognitive decline due to Alzheimer\u2019s disease. Aging Dis 2024; 15: 1688\u20131725.","journal-title":"Aging Dis"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1399"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1840"},{"key":"e_1_3_5_10_2","first-page":"863","volume-title":"Goodman & Gilman: Las Bases Farmacol\u00f3gicas de la Terap\u00e9utic","author":"Powers AC","year":"2019","unstructured":"Powers AC, D\u2019Alessio D. Cap\u00edtulo 47: P\u00e1ncreas endocrino y farmacoterapia de la diabetes mellitus y la hipoglucemia. In: Brunton LL, Chabner BA, Knollmann BC (eds) Goodman & Gilman: Las Bases Farmacol\u00f3gicas de la Terap\u00e9utic. 13 ed. Ciudad de M\u00e9xico, M\u00e9xico: McGraw-Hill Interamericana Editores, S.A., 2019, pp.863\u2013886.","edition":"13"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1122300"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094641"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164735"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0176-z"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13910"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10071043"},{"key":"e_1_3_5_18_2","unstructured":"American Diabetes Association. Understanding diabetes diagnosis. https:\/\/diabetes.org\/about-diabetes\/diagnosis (accessed 15 October 2023)."},{"key":"e_1_3_5_19_2","unstructured":"WHOCC \u2013 Guidelines https:\/\/www.whocc.no\/atc_ddd_index_and_guidelines\/guidelines\/ (accessed 14 October 2023)."},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.9060"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00314-0"},{"key":"e_1_3_5_22_2","unstructured":"R-studio https:\/\/posit.co\/ (accessed 21 December 2022)."},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.3758\/BRM.41.4.1149"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30367-6"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212293"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2009.09.022"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.233"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.14"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05165-3"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-021-00845-7"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2023.10.005"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13480"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01316-6"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz234"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-022-00568-6"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2022.111890"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00761-9"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2016.00108"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107295"},{"key":"e_1_3_5_40_2","article-title":"Alzheimer\u2019s disease drug development pipeline: 2023","volume":"9","author":"Cummings J","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G, et al. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimers Dement (N Y) 2023; 9: e12385.","journal-title":"Alzheimers Dement (N Y)"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877241304995","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877241304995","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877241304995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:28Z","timestamp":1777370968000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877241304995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/13872877241304995"],"URL":"https:\/\/doi.org\/10.1177\/13872877241304995","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}